31 August 2025 in Briefings in Bioinformatics
Cyclic peptides have emerged as a research hotspot in drug development in recent years due to their excellent stability, specificity, and cell penetration. However, existing computational models face challenges in accurately predicting the three-dimensional structures of cyclic peptides containing unnatural amino acids (unAAs), thereby limiting their drug design. The release of AlphaFold 3 has significantly enhanced the modeling capability of biomolecular complexes and enabled the inclusion of unAAs through definitions provided by the Chemical Component Dictionary (CCD). Nevertheless, its training data reliance limits its ability to accurately predict cyclic peptide structures, failing to meet the demand for precise cyclic peptide structure prediction. Based on the AlphaFold 3 framework, we developed HighFold3 by introducing the Cyclic Position Offset Encoding Matrix (CycPOEM). HighFold3 comprises two submodels: HighFold3-Linear and HighFold3–Cyclic, designed for predicting the structures of linear and cyclic peptides, respectively. Our results demonstrate that HighFold3 outperforms existing models (HighFold, HighFold2, CyclicBoltz1, NCPepFold, CABS-flex, ESMFold, and HelixFold) in cyclic peptide structure prediction. It achieves atomic-level precision in predicting cyclic peptide monomers while demonstrating enhanced accuracy and generalization capability for cyclic peptide complexes containing unAAs. This offers unprecedented technical support for the structural design and optimization of cyclic peptide–based therapeutics.
1 May 2025 in Briefings in Bioinformatics
Cyclic peptides containing unnatural amino acids possess many excellent properties and have become promising candidates in drug discovery. Therefore, accurately predicting the 3D structures of cyclic peptides containing unnatural residues will significantly advance the development of cyclic peptide-based therapeutics. Although deep learning-based structural prediction models have made tremendous progress, these models still cannot predict the structures of cyclic peptides containing unnatural amino acids. To address this gap, we introduce a novel model, HighFold2, built upon the AlphaFold-Multimer framework. HighFold2 first extends the pre-defined rigid groups and their initial atomic coordinates from natural amino acids to unnatural amino acids, thus enabling structural prediction for these residues. Then, it incorporates an additional neural network to characterize the atom-level features of peptides, allowing for multi-scale modeling of peptide molecules while enabling the distinction between various unnatural amino acids. Besides, HighFold2 constructs a relative position encoding matrix for cyclic peptides based on different cyclization constraints. Except for training using spatial structures with unnatural amino acids, HighFold2 also parameterizes the unnatural amino acids to relax the predicted structure by energy minimization for clash elimination. Extensive empirical experiments demonstrate that HighFold2 can accurately predict the 3D structures of cyclic peptide monomers containing unnatural amino acids and their complexes with proteins, with the median RMSD for Cα reaching 1.891 Å. All these results indicate the effectiveness of HighFold2, representing a significant advancement in cyclic peptide-based drug discovery.
6 March 2026 in Journal of Chemical Theory and Computation
4 April 2026 in Journal of Chemical Information and Modeling
1 September 2026 in Briefings in Bioinformatics
While AlphaFold3 has revolutionized protein structure prediction and supports noncanonical amino acids, its architecture always fails to reliably generate the closed-ring topologies characteristic of cyclic peptides. Existing adaptations, such as imposing distance constraints via an offset matrix, enforce ring geometry but cannot specify the chemical identity of the cyclization bond, leading to a restrictive bias toward amide- or disulfide-linked macrocycles. Here, we present HighFold4, a framework that adapts AlphaFold3 to explicitly incorporate user-defined chemical connectivity between residues, thereby enabling both topological closure and bond-specific cyclization. Without retraining the base model, HighFold4 achieves accurate, chemistry-aware prediction of diverse cyclic peptide conformations, as validated on 179 structures. This work established a new paradigm for the conformation construction of macrocyclic peptides with tailored ring geometry and linkage chemistry, significantly expanding the utility of deep learning in peptide-based drug discovery.
19 January 2026 in bioRxiv
Peptides, as therapeutic molecules, offer unique advantages in targeting complex protein surfaces, yet their rational design remains limited by the vastness of the sequence space and the constraints of traditional approaches. Here, we propose High-PepBinder, a sequence-only conditional diffusion framework for target-specific peptide generation. Guided by the target protein sequence, High-PepBinder adopts a dual encoder architecture that integrates protein language models (pLMs) with the diffusion model. This approach cascades the peptide generation model with an affinity classifier and enables the generation process to capture affinity-related features of the peptides through lightweight joint optimization. Due to the scarcity of protein-peptide affinity data, we constructed PepPBA, to our knowledge the most comprehensive dataset to date, and established a structure- and physics-based screening pipeline to prioritize top candidates. Results show that High-PepBinder demonstrates competitive performance across multiple peptide generation and affinity-related tasks. For representative targets, including KEAP1, XIAP, and EGFR, the generated peptides preserve key binding geometries and interface patterns of reference peptides in predicted complexes, while maintaining sequence diversity and favorable predicted properties. Overall, High-PepBinder contributes toward a general and sequence-only strategy for peptide design, offering a computational framework for expanding peptide discovery against challenging targets.